Femara (letrozole) is an aromatase inhibitor that works by suppressing the production of estrogen. In postmenopausal women estrogen is still produced in the body by the adrenal gland. Decreasing this production is a way of decreasing the risk of recurrence.

Tamoxifen on the other hand works by blocking the estrogen receptors on the cancer cell itself resulting in slower growth of the cell or cell death. Tamoxifen can be given to post or premenopausal women but Femara would only be prescribed to women that are postmenopausal. The reason being, is that a premenopausal women will still have estrogen produced by the ovaries. Femara would not be effective in this instance.

A Phase III clinical trial that is ongoing shows preliminary results that Femara is superior than Tamoxifen in women with early stage disease that are postmenopausal. The results of the study were published in the Annals of Oncology.

Cancer drug Gleevec, used for the treatment of chronic myeloid leukemia (CML), has been pulled out of another round of testing so it can get to work stopping the return of a rare stomach cancer. It's that good, according to findings announced on Thursday.

The promise of Gleevec should make it standard treatment for people with gastrointestinal stromal tumors (GIST), a stomach and intestine cancer diagnosed in 5,000 to 6,000 Americans each year.

The drug has already been used for patients whose disease is too advanced for surgery. Now it will be used for those whose tumors can be removed. The drug will be administered for at least one year post-surgery.

More than 600 people participated in this Gleevec trial. Each person took either Gleevec or a sugar pill for one year after surgery. After the one-year mark, cancer returned in 17 percent of people taking the sugar pill and in 3 percent of people taking the actual drug.

Since 50 to 90 percent of GIST cases recur over time, this is great news, say researchers who call Gleevec a highly targeted cancer drug with few side effects.

Fewer women are getting mammograms. Facilities offering mammograms are closing. Mammogram machine usage is declining. And we don't really know why.

"We're heading in the wrong direction," says Carol Lee, professor of radiology at Yale University School of Medicine and chair of the American College of Radiology's commission on breast imaging.

"If this decline holds up, it will be very worrisome," she says.

"We're looking at a possible increase in deaths if we see this continue," according to Diana Balma, vice president of public policy at Susan G. Komen for the Cure.

Studies don't show which women -- rich or poor, young or old, educated or uneducated -- are skipping these critical screenings, but there are a few possible reasons for this dangerous drop.

Think about this:

Perhaps there are fewer facilities, staffed by fewer radiologists and technologists due to high lawsuit rates and modest reimbursement. This is scary -- because the number of women old enough to get screened is increasing.

Women may be missing out on all sorts of necessary medical care because of inadequate health insurance or other access problems.

Women may be choosing, for whatever reasons, not to get mammograms, despite strong public urging that women age 40 and older get screened one time every year.

And now think about this:

Recent news about declining breast cancer rates may not be all that good. It may not be that fewer women are developing breast cancer. It may simply be that fewer women are getting early diagnoses because of irregular or nonexistent screening.

If the experimental breast cancer drug Tykerb continues to prove successful in study participants, it could be headed for FDA approval.

Tykerb, now in international study, showed in early studies to be even more effective and to have fewer side effects than similar breast cancer drug Herceptin. Both drugs are part of a cluster of targeted therapies that attack cancer cells while sparing healthy cells. Designed for use on women whose breast cancer is HER2 positive -- meaning it contains too much of an aggressive protein -- Tykerb may be a wonder drug, with the capability of effectively keeping breast cancer at bay.

Dr. Paul Goss of MA General Hospital says, "We're seeing Tykerb, which is a pill, which is easier to take, has a broader attack and gets inside cells. It's like an electrical circuit that's turned on, and Tykerb can pull the lever, the circuit breaker, and switch it off."